Marker Therapeutics, Inc.

For the period ended Dec 31, 2024. Filed Mar 31, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 31, 2025

MRKR$0.99+10.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets


· December 31, · December 31,
	2024		2023
ASSETS
Current assets:
Cash and cash equivalents		$19,192,440		$15,111,450
Prepaid expenses and deposits		483,717		988,126
Other receivables		2,346,703		1,027,815
Total current assets		22,022,860		17,127,391
Total assets		$22,022,860		$17,127,391

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued liabilities		$1,753,954		$1,745,193
Related party payable		1,710,500		1,329,655
Total current liabilities		3,464,454		3,074,848
Total liabilities		3,464,454		3,074,848

Stockholders’ equity:
Preferred stock, $0.001 par value, 5 million shares authorized, 0 shares issued and outstanding at December 31, 2024 and 2023, respectively		—		—
Common stock, $0.001 par value, 30 million shares authorized, 10.7 million and 8.9 million shares issued and outstanding as of December 31, 2024 and 2023, respectively (see Note 8)		10,708		8,891
Additional paid-in capital		465,564,876		450,329,515
Accumulated deficit		(447,017,178)		(436,285,863)
Total stockholders’ equity		18,558,406		14,052,543
Total liabilities and stockholders’ equity		$22,022,860		$17,127,391

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.